As of 2024-09-12, the Relative Valuation of BioMark Diagnostics Inc (BUX.CN) is (0.01) CAD. This relative valuation is based on P/E multiples. With the latest stock price at 0.25 CAD, the upside of BioMark Diagnostics Inc based on Relative Valuation is -103.7%.
The range of the Relative Valuation is (0.01) - (0.10) CAD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 0.5x - 6.6x | 0.6x |
| Forward P/E multiples | 0.4x - 6.2x | 0.5x |
| Fair Price | (0.01) - (0.10) | (0.01) |
| Upside | -103.2% - -141.7% | -103.7% |
| Date | P/E |
| 2024-09-11 | -14.78 |
| 2024-09-10 | -14.78 |
| 2024-09-05 | -14.19 |
| 2024-09-04 | -14.78 |
| 2024-09-03 | -13.00 |
| 2024-08-30 | -14.19 |
| 2024-08-28 | -13.60 |
| 2024-08-26 | -14.19 |
| 2024-08-23 | -13.00 |
| 2024-08-22 | -13.60 |
| 2024-08-20 | -13.00 |
| 2024-08-16 | -13.00 |
| 2024-08-15 | -13.00 |
| 2024-08-14 | -13.00 |
| 2024-08-13 | -13.60 |
| 2024-08-09 | -13.60 |
| 2024-08-08 | -13.30 |
| 2024-08-07 | -13.60 |
| 2024-08-06 | -13.60 |
| 2024-08-02 | -13.60 |
| 2024-08-01 | -14.48 |
| 2024-07-31 | -14.19 |
| 2024-07-30 | -13.60 |
| 2024-07-26 | -13.89 |
| 2024-07-25 | -14.48 |
| 2024-07-19 | -13.00 |
| 2024-07-16 | -13.00 |
| 2024-07-12 | -13.00 |
| 2024-07-11 | -13.00 |
| 2024-07-08 | -13.89 |
| 2024-07-05 | -14.19 |
| 2024-07-04 | -14.19 |
| 2024-07-02 | -13.89 |
| 2024-06-24 | -13.89 |
| 2024-06-21 | -14.19 |
| 2024-06-20 | -13.89 |